Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1632788 | 0.91 | GRM5 (0.36) | KDM4EGBA1MAPTLMNAADORA2A | |
| SCHEMBL1629932 | 0.90 | KDM4E (0.43) | KDM4ECSNK2A2CSNK2A1GBA1MAPT | |
| SCHEMBL1630961 | 0.89 | GABRA1 (0.33) | KDM4EGBA1MAPTLMNAADORA2A | |
| SCHEMBL1630790 | 0.88 | GBA1 (0.35) | KDM4ECSNK2A2CSNK2A1GBA1MAPT | |
| SCHEMBL1632239 | 0.88 | MAPT (0.33) | KDM4ECSNK2A2CSNK2A1GBA1MAPT | |
| SCHEMBL1630237 | 0.88 | CSNK2A2 (0.34) | CSNK2A2CSNK2A1GBA1MAPTLMNA | |
| SCHEMBL1632066 | 0.87 | GPR84 (0.34) | KDM4EGBA1MAPTLMNAADORA2A | |
| SCHEMBL1631283 | 0.87 | GBA1 (0.37) | KDM4ECSNK2A2CSNK2A1GBA1MAPT | |
| SCHEMBL1630804 | 0.87 | CCNC (0.34) | KDM4ECSNK2A2CSNK2A1GBA1MAPT | |
| SCHEMBL1630640 | 0.87 | CSNK2A2 (0.33) | KDM4ECSNK2A2CSNK2A1GBA1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-01-08 | — | — | US | claimed |
| US-7932270-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | KDM4E 3309/4885CSNK2A2 595/4885CSNK2A1 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.